Thrivent Financial for Lutherans Raises Holdings in Masimo Corporation $MASI

Thrivent Financial for Lutherans boosted its stake in shares of Masimo Corporation (NASDAQ:MASI) by 56.0% in the 4th quarter, HoldingsChannel reports. The fund owned 23,174 shares of the medical equipment provider’s stock after buying an additional 8,323 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Masimo were worth $3,014,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Torren Management LLC purchased a new stake in Masimo during the 4th quarter valued at about $35,000. Smartleaf Asset Management LLC boosted its holdings in Masimo by 80.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 136 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new stake in Masimo during the 4th quarter valued at about $44,000. Advisory Services Network LLC purchased a new stake in Masimo during the 3rd quarter valued at about $46,000. Finally, Danske Bank A S purchased a new stake in Masimo during the 3rd quarter valued at about $59,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Trading Up 0.1%

NASDAQ MASI opened at $178.81 on Friday. Masimo Corporation has a fifty-two week low of $125.94 and a fifty-two week high of $179.00. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.45 and a current ratio of 2.68. The stock has a 50 day simple moving average of $178.12 and a two-hundred day simple moving average of $157.09. The stock has a market cap of $9.36 billion, a P/E ratio of -16.96, a price-to-earnings-growth ratio of 1.81 and a beta of 1.13.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on MASI shares. Raymond James Financial cut Masimo from an “outperform” rating to a “market perform” rating in a report on Friday, March 27th. Piper Sandler cut Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price for the company. in a report on Tuesday, February 17th. Stifel Nicolaus set a $180.00 target price on Masimo in a report on Tuesday, February 17th. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a report on Wednesday, February 18th. Finally, Wells Fargo & Company upgraded Masimo to a “hold” rating in a report on Wednesday, March 18th. Nine investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $180.40.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.